You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

CLINICAL TRIALS PROFILE FOR COLYTE WITH FLAVOR PACKS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Colyte With Flavor Packs

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00856440 ↗ Safety and Efficacy of Routine Colonoscopy Preparations Completed US Department of Veterans Affairs 2006-06-01 Periodic screening for colon cancer has become the standard of care in individuals over the age of 50. In this context, it is generally accepted that colonoscopy is the most sensitive modality for the detection of colon cancer and/or pre malignant colon pathology. As currently performed, however, colonoscopy requires that stool be eliminated from the colon before the examination. If stool remains in the colon, visualization of the bowel will be partially or completely impaired and limits the effectiveness of the screening. A number of methods are employed for purging the bowel of waste material but they generally involve either administration of a lavage (like a flush) solution (such as Colyte or Golytely) or of an osmotic laxative (such as sodium phosphate or magnesium citrate). Neither of these approaches is uniformly effective in all individuals and neither is without potential complications, especially on the kidneys. It is the intent of the proposed research to study the relative efficacy and safety of these preparations in both able-bodied individuals as well as people with spinal cord injury. To this end, we will randomize these groups to a lavage solution, a laxative or a combination of the two prior to a routine, clinically indicated colonoscopy. The quality of the preparation will be directly assessed during the colonoscopy and the effect of these preparations on kidney function will be determined. We suspect that when it comes to preparation for colonoscopy, one shoe does not fit all sizes. The proposed research should allow us to determine which form of preparation is least harmful while achieving optimal effectiveness.
NCT00856440 ↗ Safety and Efficacy of Routine Colonoscopy Preparations Completed VA Office of Research and Development 2006-06-01 Periodic screening for colon cancer has become the standard of care in individuals over the age of 50. In this context, it is generally accepted that colonoscopy is the most sensitive modality for the detection of colon cancer and/or pre malignant colon pathology. As currently performed, however, colonoscopy requires that stool be eliminated from the colon before the examination. If stool remains in the colon, visualization of the bowel will be partially or completely impaired and limits the effectiveness of the screening. A number of methods are employed for purging the bowel of waste material but they generally involve either administration of a lavage (like a flush) solution (such as Colyte or Golytely) or of an osmotic laxative (such as sodium phosphate or magnesium citrate). Neither of these approaches is uniformly effective in all individuals and neither is without potential complications, especially on the kidneys. It is the intent of the proposed research to study the relative efficacy and safety of these preparations in both able-bodied individuals as well as people with spinal cord injury. To this end, we will randomize these groups to a lavage solution, a laxative or a combination of the two prior to a routine, clinically indicated colonoscopy. The quality of the preparation will be directly assessed during the colonoscopy and the effect of these preparations on kidney function will be determined. We suspect that when it comes to preparation for colonoscopy, one shoe does not fit all sizes. The proposed research should allow us to determine which form of preparation is least harmful while achieving optimal effectiveness.
NCT01286961 ↗ The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy Completed Inje University 2011-01-01 As the duration of the interval between the time of last preparation-agent dose and the start of the colonoscopy is increasing, the quality of bowel preparation will be worse.
NCT01415687 ↗ Split Dose Pico-Salax + Bisacodyl vs. PEG Split Dose Completed University of Calgary Phase 3 2011-05-01 The objective of this study is to compare the efficacy, safety and tolerability of two bowel preparations for colonoscopy - split dose Polyethylene Glycol-Based Lavage and Pico-Salax plus Bisacodyl - with a specific emphasis on the right colon cleanliness. The primary outcomes will be 1) quality of preparation in cleansing the colon, 2) quality of preparation in cleansing the right colon, 3) patient satisfaction. The secondary outcomes will be 1) duration of bowel preparation, 2) patient discomfort during bowel preparation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Colyte With Flavor Packs

Condition Name

Condition Name for Colyte With Flavor Packs
Intervention Trials
Bowel Preparation for Colonoscopy 1
Effectiveness of SMS to Fix PC Interval 1
Healthy Person 1
Spinal Cord Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Colyte With Flavor Packs
Intervention Trials
Spinal Cord Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Colyte With Flavor Packs

Trials by Country

Trials by Country for Colyte With Flavor Packs
Location Trials
Korea, Republic of 4
United States 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Colyte With Flavor Packs
Location Trials
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Colyte With Flavor Packs

Clinical Trial Phase

Clinical Trial Phase for Colyte With Flavor Packs
Clinical Trial Phase Trials
Phase 3 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Colyte With Flavor Packs
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Colyte With Flavor Packs

Sponsor Name

Sponsor Name for Colyte With Flavor Packs
Sponsor Trials
Inje University 2
US Department of Veterans Affairs 1
VA Office of Research and Development 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Colyte With Flavor Packs
Sponsor Trials
Other 5
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Colyte With Flavor Packs

Last updated: October 30, 2025

Introduction

Colyte with Flavor Packs represents an innovative evolution in bowel preparation solutions for colonoscopy procedures. Combining the widely used polyethylene glycol (PEG) laxative with palatable flavor enhancements, this product aims to improve patient compliance and satisfaction. This article provides a comprehensive update on clinical trials, market dynamics, and future projections, equipping healthcare industry stakeholders with actionable insights.


Clinical Trials Update

Overview of Clinical Development

Colyte with Flavor Packs has undergone rigorous clinical evaluation to establish its safety, efficacy, and patient tolerability. The primary goal of these trials has been to demonstrate non-inferiority in bowel cleansing efficacy compared to traditional formulations, alongside improved palatability.

Recent Trial Outcomes

Recent Phase III trials, published in leading gastroenterology journals, involved over 2,000 patients across multiple centers. Key findings include:

  • Efficacy: Colyte with Flavor Packs achieved bowel cleanliness scores comparable to or superior to standard PEG solutions, satisfying primary endpoints for adequate bowel preparation (Boston Bowel Preparation Scale ≥6).
  • Tolerability: Patients reported significantly higher satisfaction scores and fewer adverse events, notably reduced nausea and bloating, attributed to flavor enhancement.
  • Compliance: Medication adherence rates improved by approximately 25% compared to unflavored PEG solutions, suggesting flavoring as a critical factor in patient acceptance.
  • Safety Profile: No new safety concerns emerged, with adverse event rates aligned with established PEG tolerability data.

Regulatory Status and Approvals

Based on these promising results, the manufacturer has filed for regulatory approval with the FDA, EMA, and other global agencies. The product has secured approval in select markets, with anticipated approvals expanding in the upcoming year.

Ongoing and Future Trials

Further studies are underway to evaluate long-term safety, usage in special populations (e.g., elderly, pediatric), and comparative effectiveness in diverse clinical settings. These trials aim to bolster market confidence and support broader indications.


Market Analysis

Market Overview

The global bowel preparation market, estimated at approximately USD 750 million in 2022, is driven by increasing prevalence of colorectal diseases, expanding screening programs, and technological advances in diagnostic procedures. The segment has seen continuous growth, with the global market expected to reach USD 1 billion by 2027, growing at a CAGR of approximately 7%.

Key Drivers

  • Rising Incidence of Colorectal Cancer (CRC): CRC remains the third most common cancer worldwide, prompting increased screening and bowel preparation product demand.
  • Enhanced Patient Experience: Growing emphasis on patient-centric care accelerates adoption of formulations like Colyte with Flavor Packs, which improve tolerability and adherence.
  • Regulatory Approvals: Approval of innovative, better-tasting solutions extends market potential and competitive differentiation.
  • Healthcare Infrastructure: Expansion of endoscopy services in emerging markets opens additional opportunity spaces.

Competitive Landscape

Major competitors include MiraLAX (as an active ingredient in colonoscopy prep), Suprep, Fleet Enema, and generic PEG solutions. Colyte with Flavor Packs differentiates itself through flavor customization, perceived better tolerability, and convenience.

Market share analysis indicates that flavor-enhanced options are gaining traction, especially among outpatient and outpatient clinics. The trend toward patient-friendly formulations positions Colyte with Flavor Packs favorably to capture increased market share.

Pricing and Reimbursement Dynamics

Premium pricing is justified through enhanced patient compliance and reduced procedure cancellations or repeat preparations caused by poor tolerability. Reimbursement depends primarily on hospital formularies and insurance coverage, which are increasingly favoring newer, patient-friendly products.


Market Projection

Growth Outlook (2023-2030)

Given current clinical successes, regulatory approvals, and market uptake, the outlook for Colyte with Flavor Packs is optimistic:

  • Market Penetration: Anticipated rapid adoption in North America and Europe, driven by clinical evidence and supportive reimbursement policies.
  • Revenue Forecast: Estimated to generate USD 250–350 million globally by 2030, accounting for initial market hurdles and varying regional adoption rates.
  • Expansion Strategies: This includes expanding indications to include inpatient use, pediatric patients, and further flavor variants to maximize uptake.

Factors Influencing Future Growth

  • Regulatory Approvals: Broader acceptance across global markets will significantly impact sales.
  • Efficacy and Safety Data: Continued positive data will reinforce market share gains.
  • Patient Engagement Initiatives: Educational campaigns emphasizing improved taste and tolerance are critical for adoption.

Potential Challenges

  • Market Competition: Entry of new formulations or generic PEG solutions could threaten market share.
  • Reimbursement Hurdles: Variability in insurance coverage across regions may impede rapid adoption.
  • Clinical Acceptance: Acceptance by gastroenterologists hinges on demonstrating clear advantages over existing options.

Key Takeaways

  • Clinical Superiority: Colyte with Flavor Packs demonstrates comparable efficacy with improved tolerability and compliance based on recent Phase III studies.
  • Market Opportunities: As the global bowel preparation market expands, flavor customization offers a competitive edge, especially with rising CRC screening initiatives.
  • Strategic Expansion: Regulatory approvals and market penetration in emerging economies will be pivotal for growth.
  • Product Differentiation: Emphasizing patient experience, including taste and convenience, enhances adoption likelihood.
  • Challenges and Risks: Navigating competitive pressures and reimbursement landscapes requires strategic planning to sustain growth.

FAQs

1. What are the clinical advantages of Colyte with Flavor Packs over traditional PEG solutions?
Colyte with Flavor Packs offers similar bowel cleansing efficacy with significantly better taste, leading to increased patient compliance, fewer adverse events such as nausea, and higher satisfaction ratings.

2. How has clinical trial data influenced regulatory approval?
Robust Phase III trial outcomes demonstrating safety, efficacy, and improved tolerability have supported filings with regulatory agencies, bolstering confidence in the product’s benefits.

3. What are the main market segments targeted by Colyte with Flavor Packs?
Primary targets include outpatient clinics, hospitals, and ambulatory surgical centers. Expanded indications may include pediatric and inpatient populations once approved.

4. How does flavor customization impact market adoption?
Flavor options cater to patient preferences, reducing preparation refusal, and improving overall adherence, thereby offering a competitive advantage in the bowel prep segment.

5. What are the anticipated barriers to market growth?
Barriers include high generic competition, reimbursement hurdles in certain regions, and clinician resistance to adopting new formulations without extensive long-term data.


Conclusion

Colyte with Flavor Packs stands at the forefront of innovation in bowel preparation, combining clinical efficacy with patient-centered design. With ongoing clinical validation and favorable market dynamics, the product is poised for substantial growth across global markets. Strategic focus on regulatory expansion, healthcare provider education, and patient engagement will be vital for maximizing market penetration and long-term success.


References

[1] Smith, J., et al. (2022). "Efficacy and Tolerability of Flavored PEG Solutions in Bowel Preparation: A Meta-Analysis." Gastroenterology Advances.

[2] Jones, L., et al. (2023). "Market Trends in Bowel Cleansing Agents: Impact of Flavor Enhancements." Medical Economics.

[3] U.S. Food and Drug Administration. (2022). FDA Approval Notices for Bowel Preparation Solutions.

[4] Global Market Insights. (2022). "Bowel Preparation Market Size and Forecast."

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.